AR093297A1 - Formulacion liquida que comprende un compuesto neutralizante de gm-csf - Google Patents
Formulacion liquida que comprende un compuesto neutralizante de gm-csfInfo
- Publication number
- AR093297A1 AR093297A1 ARP130103964A ARP130103964A AR093297A1 AR 093297 A1 AR093297 A1 AR 093297A1 AR P130103964 A ARP130103964 A AR P130103964A AR P130103964 A ARP130103964 A AR P130103964A AR 093297 A1 AR093297 A1 AR 093297A1
- Authority
- AR
- Argentina
- Prior art keywords
- neutralizing compound
- csf neutralizing
- composition according
- formulation
- buffer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formulaciones acuosas que comprenden un compuesto neutralizante de GM-CSF en concentraciones de al menos aproximadamente 20 mg/ml, un modificador de la tonicidad y un buffer, en donde la composición es estable. Los ingredientes de la formulación preferiblemente proveen estabilidad al compuesto neutralizante de GM-CSF en vista del almacenamiento a largo plazo. En un aspecto preferido, la formulación es para uso en terapia, preferiblemente para uso en el tratamiento de trastornos inflamatorios y autoinmunes, incluyendo preferiblemente trastornos alérgicos y psoriáticos, así como también trastornos artríticos y asmáticos. Adicionalmente, se provee un kit que comprende la formulación. Reivindicación 3: La composición de acuerdo con la reivindicación 1 ó 2, en donde el modificador de la tonicidad está seleccionado a partir de manitol, sorbitol, sacarosa y/o trehalosa. Reivindicación 4: La composición de acuerdo con una cualquiera de las reivindicaciones 1 a 3, en donde el buffer está seleccionado a partir de buffer de histidina, de acetato y/o de citrato. Reivindicación 9: La composición de acuerdo con una cualquiera de las reivindicaciones 1 a 8, en donde el compuesto neutralizante de GM-CSF está seleccionado a partir del grupo que consiste de un polipéptido, un péptido mimético, un ácido nucleico, y una molécula pequeña.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720892P | 2012-10-31 | 2012-10-31 | |
| EP12199191 | 2012-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093297A1 true AR093297A1 (es) | 2015-05-27 |
Family
ID=47504727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103964A AR093297A1 (es) | 2012-10-31 | 2013-10-30 | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9919051B2 (es) |
| EP (2) | EP2914290B1 (es) |
| JP (1) | JP6346189B2 (es) |
| KR (1) | KR102106914B1 (es) |
| CN (1) | CN104768580B (es) |
| AR (1) | AR093297A1 (es) |
| AU (1) | AU2013340845B2 (es) |
| BR (1) | BR112015009259B8 (es) |
| CA (1) | CA2889307C (es) |
| EA (1) | EA032829B1 (es) |
| MX (1) | MX363807B (es) |
| PH (1) | PH12015500864A1 (es) |
| TW (1) | TWI639440B (es) |
| WO (1) | WO2014068026A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015028657A1 (en) | 2013-08-30 | 2015-03-05 | Takeda Gmbh | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
| ES2974895T3 (es) * | 2014-05-07 | 2024-07-02 | Takeda Pharmaceuticals Co | Formulación líquida que comprende un compuesto neutralizante de GM-CSF |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946765B1 (en) | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| KR101953706B1 (ko) * | 2016-09-19 | 2019-03-05 | 아이-맵 | 항-gm-csf 항체 및 이것의 사용 |
| BR112019018022A2 (pt) * | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| CN107167613B (zh) * | 2017-06-22 | 2018-10-02 | 深圳清华大学研究院 | 用于等离子体金芯片的蛋白点样缓冲液 |
| EP3996740A4 (en) * | 2019-07-12 | 2023-07-05 | Contrafect Corporation | THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| AU2001232267A1 (en) | 2000-02-14 | 2001-08-20 | Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases | Remedies for hepatitis c |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| US9415102B2 (en) * | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| CA2562771C (en) * | 2004-04-12 | 2013-04-09 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
| DE602004021773D1 (de) | 2004-05-05 | 2009-08-13 | Micromet Ag | Herstellung eines einkettigen fv Antikörperfragments |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0517202A (pt) | 2004-12-16 | 2008-09-30 | Genentech Inc | método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| CN101184777B (zh) * | 2005-04-18 | 2013-07-17 | 安进研发（慕尼黑）股份有限公司 | 人粒细胞巨噬细胞集落刺激因子的抗体中和剂 |
| PL3620171T3 (pl) | 2005-05-18 | 2022-08-08 | Morphosys Ag | Przeciwciała anty-gm-csf i ich zastosowania |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| HRP20170024T1 (hr) | 2006-02-08 | 2017-03-10 | Morphotek, Inc. | Antigeni peptidi gm-csf i protutijela protiv gm-csf |
| PT2423229E (pt) | 2006-03-27 | 2013-08-22 | Medimmune Ltd | Membro de ligação para o recetor de gm-csf |
| CN101605547A (zh) * | 2006-11-21 | 2009-12-16 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| WO2009002521A2 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PT2215119E (pt) * | 2007-11-13 | 2013-02-11 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem |
| EP2280732B1 (en) | 2008-04-28 | 2018-10-17 | Humanigen, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CN104338136A (zh) | 2008-04-29 | 2015-02-11 | 安进研发（慕尼黑）股份有限公司 | 用于治疗的gm-csf和il-17抑制剂 |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| AU2010244525B2 (en) | 2009-05-05 | 2013-03-28 | Morphosys Ag | Treatment for multiple sclerosis |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| MX2012007676A (es) * | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Nueva formulacion de anticuerpo. |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| MY175388A (en) | 2012-09-20 | 2020-06-23 | Morphosys Ag | Treatment for rheumatoid arthritis |
| EP2914289B1 (en) * | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
-
2013
- 2013-10-30 AR ARP130103964A patent/AR093297A1/es not_active Application Discontinuation
- 2013-10-31 EP EP13798590.9A patent/EP2914290B1/en active Active
- 2013-10-31 EP EP20166154.3A patent/EP3744344A1/en not_active Withdrawn
- 2013-10-31 EA EA201590509A patent/EA032829B1/ru not_active IP Right Cessation
- 2013-10-31 US US14/429,204 patent/US9919051B2/en active Active
- 2013-10-31 CA CA2889307A patent/CA2889307C/en active Active
- 2013-10-31 WO PCT/EP2013/072761 patent/WO2014068026A1/en not_active Ceased
- 2013-10-31 MX MX2015005237A patent/MX363807B/es active IP Right Grant
- 2013-10-31 JP JP2015538509A patent/JP6346189B2/ja active Active
- 2013-10-31 KR KR1020157008428A patent/KR102106914B1/ko active Active
- 2013-10-31 AU AU2013340845A patent/AU2013340845B2/en active Active
- 2013-10-31 CN CN201380056759.5A patent/CN104768580B/zh active Active
- 2013-10-31 BR BR112015009259A patent/BR112015009259B8/pt active IP Right Grant
- 2013-10-31 TW TW102139662A patent/TWI639440B/zh active
-
2015
- 2015-04-17 PH PH12015500864A patent/PH12015500864A1/en unknown
-
2018
- 2018-03-15 US US15/922,777 patent/US10758621B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10758621B2 (en) | 2020-09-01 |
| AU2013340845A1 (en) | 2015-03-26 |
| KR102106914B1 (ko) | 2020-05-08 |
| US20150314001A1 (en) | 2015-11-05 |
| AU2013340845B2 (en) | 2018-02-22 |
| EP2914290B1 (en) | 2020-04-01 |
| EA201590509A1 (ru) | 2015-10-30 |
| KR20150075083A (ko) | 2015-07-02 |
| PH12015500864B1 (en) | 2015-06-22 |
| EA032829B1 (ru) | 2019-07-31 |
| TWI639440B (zh) | 2018-11-01 |
| BR112015009259A2 (es) | 2017-08-22 |
| EP2914290A1 (en) | 2015-09-09 |
| EP3744344A1 (en) | 2020-12-02 |
| CA2889307C (en) | 2021-11-23 |
| TW201438735A (zh) | 2014-10-16 |
| WO2014068026A1 (en) | 2014-05-08 |
| US20180207278A1 (en) | 2018-07-26 |
| BR112015009259B1 (pt) | 2022-05-17 |
| US9919051B2 (en) | 2018-03-20 |
| MX2015005237A (es) | 2015-10-29 |
| CA2889307A1 (en) | 2014-05-08 |
| CN104768580A (zh) | 2015-07-08 |
| MX363807B (es) | 2019-04-03 |
| JP2015536931A (ja) | 2015-12-24 |
| JP6346189B2 (ja) | 2018-06-20 |
| CN104768580B (zh) | 2018-11-02 |
| HK1214761A1 (en) | 2016-08-05 |
| PH12015500864A1 (en) | 2015-06-22 |
| BR112015009259B8 (pt) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093297A1 (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf | |
| MX2016014411A (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
| ES2654102T3 (es) | Formulaciones líquidas para conjugado de C-CSF de acción prolongada | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| AR113034A2 (es) | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| JP2017222654A5 (es) | ||
| AR081364A1 (es) | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion | |
| BR112015025172A2 (pt) | composição farmacêutica | |
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| BR112015014034A2 (pt) | inibidores de irak e usos dos mesmos | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| JP2017514924A5 (es) | ||
| NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
| MX2016006651A (es) | Soluciones para incrementar la estabilidad y la vida util de una solucion de conservacion de organos y tejidos. | |
| ES2519240A2 (es) | Preparación de caspofungina de bajo contenido de impurezas, método para preparar la misma, y uso de la misma | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| EA201200754A1 (ru) | Традиционное китайское лекарственное средство, содержащее экстракты дан-шен (danshen) и сан-ки (sanqi), и его применение | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |